Predicting response to TNF antagonists in rheumatoid arthritis

The promise of pharmacogenetics research using clinical registries

Jeffrey D. Greenberg, Harry Ostrer

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Despite the demonstrated efficacy of three different classes of biologic response modifiers (BRMs) for the treatment of rheumatoid arthritis (RA), there are currently no clinical predictors or biomarkers that can rationally guide physicians in the selection of BRMs for individual patients. One promising area of translational research for patients with RA is the field of pharmacogenetics. In the absence of industry-sponsored pharmacogenetic studies of BRMs, longitudinal clinical registries may represent the most promising setting for identifying genetic biomarkers. This review focuses on published pharmacogenetic studies of TNF antagonists and discusses related methodologic issues for pharmacogenetic research using clinical registries.

Original languageEnglish (US)
Pages (from-to)139-142
Number of pages4
JournalBulletin of the NYU Hospital for Joint Diseases
Volume65
Issue number2
StatePublished - 2007
Externally publishedYes

Fingerprint

Pharmacogenetics
Registries
Rheumatoid Arthritis
Biomarkers
Translational Medical Research
Research
Industry
Physicians
Pharmacogenomic Testing
Therapeutics

ASJC Scopus subject areas

  • Bioengineering
  • Rheumatology
  • Surgery

Cite this

@article{c163bb9c2fbc4d11be2bd155831a24b2,
title = "Predicting response to TNF antagonists in rheumatoid arthritis: The promise of pharmacogenetics research using clinical registries",
abstract = "Despite the demonstrated efficacy of three different classes of biologic response modifiers (BRMs) for the treatment of rheumatoid arthritis (RA), there are currently no clinical predictors or biomarkers that can rationally guide physicians in the selection of BRMs for individual patients. One promising area of translational research for patients with RA is the field of pharmacogenetics. In the absence of industry-sponsored pharmacogenetic studies of BRMs, longitudinal clinical registries may represent the most promising setting for identifying genetic biomarkers. This review focuses on published pharmacogenetic studies of TNF antagonists and discusses related methodologic issues for pharmacogenetic research using clinical registries.",
author = "Greenberg, {Jeffrey D.} and Harry Ostrer",
year = "2007",
language = "English (US)",
volume = "65",
pages = "139--142",
journal = "Bulletin of the Hospital for Joint Disease (2013)",
issn = "2328-4633",
publisher = "J.Michael Ryan Publishing Inc.",
number = "2",

}

TY - JOUR

T1 - Predicting response to TNF antagonists in rheumatoid arthritis

T2 - The promise of pharmacogenetics research using clinical registries

AU - Greenberg, Jeffrey D.

AU - Ostrer, Harry

PY - 2007

Y1 - 2007

N2 - Despite the demonstrated efficacy of three different classes of biologic response modifiers (BRMs) for the treatment of rheumatoid arthritis (RA), there are currently no clinical predictors or biomarkers that can rationally guide physicians in the selection of BRMs for individual patients. One promising area of translational research for patients with RA is the field of pharmacogenetics. In the absence of industry-sponsored pharmacogenetic studies of BRMs, longitudinal clinical registries may represent the most promising setting for identifying genetic biomarkers. This review focuses on published pharmacogenetic studies of TNF antagonists and discusses related methodologic issues for pharmacogenetic research using clinical registries.

AB - Despite the demonstrated efficacy of three different classes of biologic response modifiers (BRMs) for the treatment of rheumatoid arthritis (RA), there are currently no clinical predictors or biomarkers that can rationally guide physicians in the selection of BRMs for individual patients. One promising area of translational research for patients with RA is the field of pharmacogenetics. In the absence of industry-sponsored pharmacogenetic studies of BRMs, longitudinal clinical registries may represent the most promising setting for identifying genetic biomarkers. This review focuses on published pharmacogenetic studies of TNF antagonists and discusses related methodologic issues for pharmacogenetic research using clinical registries.

UR - http://www.scopus.com/inward/record.url?scp=34548452460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548452460&partnerID=8YFLogxK

M3 - Article

VL - 65

SP - 139

EP - 142

JO - Bulletin of the Hospital for Joint Disease (2013)

JF - Bulletin of the Hospital for Joint Disease (2013)

SN - 2328-4633

IS - 2

ER -